JP2013544850A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544850A5
JP2013544850A5 JP2013542235A JP2013542235A JP2013544850A5 JP 2013544850 A5 JP2013544850 A5 JP 2013544850A5 JP 2013542235 A JP2013542235 A JP 2013542235A JP 2013542235 A JP2013542235 A JP 2013542235A JP 2013544850 A5 JP2013544850 A5 JP 2013544850A5
Authority
JP
Japan
Prior art keywords
azabicyclo
dichlorophenyl
hexane
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013542235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544850A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063193 external-priority patent/WO2012075473A1/en
Publication of JP2013544850A publication Critical patent/JP2013544850A/ja
Publication of JP2013544850A5 publication Critical patent/JP2013544850A5/ja
Pending legal-status Critical Current

Links

JP2013542235A 2010-12-03 2011-12-02 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用 Pending JP2013544850A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41976910P 2010-12-03 2010-12-03
US61/419,769 2010-12-03
PCT/US2011/063193 WO2012075473A1 (en) 2010-12-03 2011-12-02 Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017000485A Division JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Publications (2)

Publication Number Publication Date
JP2013544850A JP2013544850A (ja) 2013-12-19
JP2013544850A5 true JP2013544850A5 (enExample) 2015-01-29

Family

ID=46172308

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013542235A Pending JP2013544850A (ja) 2010-12-03 2011-12-02 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2017000485A Pending JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2018177184A Pending JP2019031502A (ja) 2010-12-03 2018-09-21 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017000485A Pending JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2018177184A Pending JP2019031502A (ja) 2010-12-03 2018-09-21 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Country Status (8)

Country Link
US (5) US20120258994A1 (enExample)
EP (1) EP2646019A4 (enExample)
JP (3) JP2013544850A (enExample)
KR (1) KR20140053822A (enExample)
AU (1) AU2011336318A1 (enExample)
BR (1) BR112013013572A2 (enExample)
CA (1) CA2834713A1 (enExample)
WO (1) WO2012075473A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20150366501A1 (en) * 2013-01-28 2015-12-24 Brc Operations Pty Limited White matter diffusion tensor imaging test to predict treatment outcomes in medical treatment
WO2014134569A1 (en) * 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
EP2994129A4 (en) * 2013-05-07 2017-01-25 Euthymic Bioscience, Inc. Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
JP2016535794A (ja) * 2013-11-11 2016-11-17 インパックス ラボラトリーズ,インコーポレーテッド 急速崩壊性製剤及びその使用法
CN104683094B (zh) * 2013-11-29 2018-10-26 上海华虹集成电路有限责任公司 用于rsa密码的蒙哥马利阶梯算法
CA2936108A1 (en) 2013-12-09 2015-07-09 Neurovance, Inc. Novel compositions
WO2018002926A1 (en) 2016-06-28 2018-01-04 Seach Sarid Ltd. A dosage form for vaporization and smoking
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
WO2019223753A1 (zh) * 2018-05-23 2019-11-28 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020142545A1 (en) 2018-12-31 2020-07-09 Ethismos Research, Inc. Novel methods
US11554154B2 (en) * 2020-07-22 2023-01-17 Biolite, Inc. Polygala extract for the treatment of major depressive disorder
CN118176001A (zh) * 2021-08-31 2024-06-11 埃塞斯莫斯研究股份有限公司 预防和治疗疼痛和相关症状的方法
CN116813547A (zh) * 2023-06-29 2023-09-29 爱斯特(成都)生物制药股份有限公司 一种制备3-氮杂双环[3,2,1]辛烷盐酸盐的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
NZ589033A (en) * 2004-08-18 2012-06-29 Dov Pharmaceutical Inc Novel polymorphs of azabicyclohexane
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders

Similar Documents

Publication Publication Date Title
KR20210134313A (ko) 심리적, 인지적, 행동적 및/또는 기분 장애의 치료를 위한 5ht 수용체 아고니스트를 포함하는 조성물 및 방법
RU2384333C2 (ru) Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
CN101431990B (zh) 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-酚和对乙酰氨基酚的药物结合
JPH08208471A (ja) 薬物反応の増強作用
JP2016210798A5 (enExample)
JP2017509686A5 (enExample)
EP1858516A1 (en) Pharmaceutical compositions for the treatment and/or prevention of depression
JP2007533686A5 (enExample)
JP2009538331A (ja) 抑うつ障害のための治療
KR20070087678A (ko) 수면 장애용 약제 조성물
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
JP2009536176A5 (enExample)
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
JP2019031502A5 (enExample)
CN103547260A (zh) 用于治疗中枢系统疾病的包含Brexpiprazole或其盐和第二种药物的组合
JP2002515435A (ja) 鬱病処置のための組合せ治療
JP2005523334A5 (enExample)
JP2004527551A (ja) エナンチオ純粋なエスシタロプラムの使用方法
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
CN103041389A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
RU2010151969A (ru) Фармацевтическая композиция для лечения преждевременной эякуляции
JPS61200912A (ja) 鎮痛剤組成物
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法